Koninklijke DSM NV (RDSMY) Stock Rating Lowered by Zacks Investment Research

Koninklijke DSM NV (OTCMKTS:RDSMY) was downgraded by Zacks Investment Research from a “buy” rating to a “sell” rating in a research note issued on Wednesday.

According to Zacks, “DSM N V ADR is involved in the Chemicals Industry. Their main focus is on base materials, performance materials, materials processing, base chemicals and fine chemicals and coating resins. They are also involved in the exploration and development of oil and natural gas deposits in the North Sea, as well as the licensing of chemical technology and know-how; in addition the company produces ingredients for bakery products. DSM is a world market leader in a number of products, including caprolactam, melamine and EPDM synthetic rubber. “

Shares of Koninklijke DSM NV (OTCMKTS:RDSMY) opened at 17.065 on Wednesday. The stock has a 50 day moving average price of $17.10 and a 200 day moving average price of $15.61. Koninklijke DSM NV has a one year low of $11.33 and a one year high of $17.88. The firm has a market cap of $11.91 billion, a price-to-earnings ratio of 39.848 and a beta of 1.44.

About Koninklijke DSM NV

Koninklijke DSM N.V. (Royal DSM) is a global science-based company, engaged in offering health, nutrition and materials. The Company’s segments include Nutrition, Performance Materials, Innovation Center and Corporate Activities. Its Nutrition segment includes DSM Nutritional Products and DSM Food Specialties.

Get a free copy of the Zacks research report on Koninklijke DSM NV (RDSMY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Koninklijke DSM NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Koninklijke DSM NV and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.